Fundz

Cyclacel Pharmaceuticals

Berkeley Heights, New Jersey, United States · Biopharma, Biotechnology, Pharmaceutical · 13 employees

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis biology. The Company's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.

Funding history

  • Series seed — $1.0M — Mar 2025
  • Series series e — $1.0M — Mar 2025
  • Series seed — $2.1M — Nov 2024
  • Funding Round — $8.0M — May 2024
  • Funding Round — $7.0M — Jan 2021

Recent signals

  • Jul 01, 2026: SEC 8-K (8.01): On July 1, 2026, the Board of Directors of Bio Green Med Solution, Inc. declared a quarterly cash dividend of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock. This dividend is scheduled to be paid on August 1, 2026, to stockholders of record as of the close of business on July 23, 2026. The declaration of this dividend indicates the Company's positive cash flow position and commitment to return value to its investors, reflecting a strategic move to strengthen shareholder relations amidst its ongoing business activities.
  • Nov 06, 2025: Bio Green Med Solution Enters Warrant Exchange Agreement
  • Nov 05, 2025: SEC 8-K (1.01): On November 5, 2025, Bio Green Med Solution, Inc. entered into a Warrant Exchange Agreement with certain accredited investors to exchange existing warrants for an aggregate of 1,402,605 shares of its common stock. This agreement signifies a strategic move by the Company to manage its equity and potentially strengthen its capital structure. The Exchanged Warrants were previously issued under a separate arrangement, and this new agreement aims to optimize investor relationships and financial flexibility. The event date aligns with the recent filing, confirming its relevance and timeliness.
  • Mar 25, 2025: Raised $1.0M in Series seed
  • Mar 24, 2025: Raised $1.0M in Series series e
  • Dec 05, 2024: Launched Cyclacel Pharmaceuticals Announces Exploration of Strategic Alternatives to Preserve Cash and Reduce Costs.
  • Nov 26, 2024: Raised $2.1M in Series seed
  • Nov 14, 2024: Cyclacel Pharmaceuticals Closes Warrant Exercise, Raises $2.1 Million

See plans & pricing → Track Cyclacel Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.